The development strategy for an effective tetravalent dengue vaccine has consisted of the clinical evaluation of monovalent vaccine candidates for each of the four serotypes with the goal of selecting suitable candidates for inclusion in a tetravalent formulation. Several Phase I clinical studies in adults were completed to evaluate five different tetravalent admixtures of each vaccine candidate. From this set of data, an initial promising admixture (TV003: DEN1del30, DEN2/4del30, DEN3del30/31, DEN4del30) was selected; however, additional expanded clinical evaluation identified a optimal admixture (TV005) that induces an unprecedented level of neutralizing antibody that is both balanced among the serotypes and sufficient to provide sterile immunity against a second dose administered at six months. Both TV003 and TV005 contain the same set of attenuated viruses, although in TV005, the DENV-2 component is present at a 10-fold higher dose than previously formulated in TV003. Following a single dose of TV005, the frequency of seroconversion in vaccinees to the individual serotypes 1 - 4 reached a remarkable 92%, 97%, 97%, and 97%, respectively, with 90% of vaccinees achieving a tetravalent antibody response. These data suggest that a single dose of vaccine may be sufficiently immunogenic, which points to a significant advantage of the LID vaccine compared to other live attenuated DENV vaccines which require two or three doses to achieve a similar result. The selection of an optimal tetravalent admixture has enabled the further development of the vaccine by several manufacturers located in Brazil, India, Vietnam, and the United States. Through on-going technological and scientific support, these licensees are making significant progress in the development of the vaccine and Phase 2 trials are underway in Brazil. Through an Interagency Agreement initiated with the Walter Reed Army Institute of Research, a Phase 2 study has been designed to evaluate the tetravalent vaccine in subjects of decreasing age in Bangkok, Thailand. At LID, clinical evaluation of TV003 and TV005 in a single dose vaccination study followed by challenge with a safety-tested DENV-2 stain is currently underway (NCT02021968 and NCT02021968). Should future studies of this vaccine prove it to be efficacious, the vaccine could be a cost-effective means of controlling dengue in endemic areas and a tremendous public health asset. The development of effective vaccination strategies against dengue virus infection and clinically significant disease remains a task of high global public health value and significance, while also being a challenge of significant complexity. A recent efficacy trial of the most advanced dengue vaccine candidate, demonstrated only partial protection against all four DENV serotypes, despite three subsequent immunizations and detection of measurable neutralizing antibodies to each serotype in most subjects. These results have challenged the hypothesis that seroconversion is the only reliable correlate of protection. We have shown that CD8(+) T cell responses in vaccinees were readily detectable and comparable to natural dengue virus infection. Detailed knowledge of the T cell response may further contribute to the identification of robust correlates of protection in natural immunity and vaccination against DENV.

Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code
Gallichotte, Emily N; Baric, Thomas J; Yount Jr, Boyd L et al. (2018) Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog 14:e1006934
Nguyen, Thi Hanh Tien; Clapham, Hannah E; Phung, Khanh Lam et al. (2018) Methods to discriminate primary from secondary dengue during acute symptomatic infection. BMC Infect Dis 18:375
Popper, Stephen J; Strouts, Fiona R; Lindow, Janet C et al. (2018) Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers. J Infect Dis :
Ricciardi, Michael J; Magnani, Diogo M; Grifoni, Alba et al. (2017) Ontogeny of the B- and T-cell response in a primary Zika virus infection of a dengue-naïve individual during the 2016 outbreak in Miami, FL. PLoS Negl Trop Dis 11:e0006000
Grifoni, Alba; Angelo, Michael; Sidney, John et al. (2017) Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2?30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. J Virol 91:
Angelo, Michael A; Grifoni, Alba; O'Rourke, Patrick H et al. (2017) Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity. J Virol 91:
Whitehead, Stephen S; Durbin, Anna P; Pierce, Kristen K et al. (2017) In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis 11:e0005584
Whitehead, Stephen S; Subbarao, Kanta (2017) Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination. Cold Spring Harb Perspect Biol :
Durbin, Anna P; Whitehead, Stephen S (2017) Zika Vaccines: Role for Controlled Human Infection. J Infect Dis 216:S971-S975
Pierce, Kristen K; Whitehead, Stephen S; Kirkpatrick, Beth D et al. (2017) A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4?30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. J Infect Dis 215:52-55

Showing the most recent 10 out of 24 publications